New: Revised USP Monographs of Spectroscopic Methods
Six updated chapters about Atom Absorption Spectroscopy, Infrared Spectroscopy and UV-Vis Spectroscopy were published in the Pharmacopeial Forum 37 (5) from September 2011. These new chapters should replace the existing General Chapter <851> "Spectrophotometry and Light-Scattering". The General Chapter about Fluorescence Spectroscopy should also be revised in the coming year.
From now on, these topics will always be split into two parts and presented in two different chapters: namely legally binding chapters (<8xy> series) and strong guidance chapters (<18xy> series). Numbers under 1000 are seen as binding whereas numbers over 1000 are rather to be understood as strong guidance.
In concrete terms, following General Chapters are concerned:
- <852> Atomic Absorption Spectroscopy
- <854> Mid-Infrared Spectroscopy
- <857> Ultraviolet-Visible Spectroscopy
- <1852> Atomic Absorption Spectroscopy - Theory and Practice
- <1854> Mid-Infrared Spectroscopy - Theory and Practice
- <1857> Mid-Infrared Spectroscopy - Theory and Practice
Chapters <852>, <854> and <857> all have the same structure, i.e.:
- Introduction
- Qualification
- Procedure
- Validation and verification
For some time now, the access to the Pharmacopoeial Forum has been free. You only need to register. More information can be found here.
These newly proposed USP chapters will also be presented by Dr Chris Burgess during the ECA Education Course "Lab Equipment Qualification" in Amsterdam, Netherlands, from 12-14 October 2011. Dr Burgess is a member of the current "USP Councils of Experts on General Chapters".
Author:
Dr Günter Brendelberger
CONCEPT HEIDELBERG (a service provider entrusted by the ECA Foundation)
Related GMP News
18.12.2025FDA Form 483: Excel-Based Data Falsification and Duplicate Log Books
18.12.2025Questions and Answers on System Suitability Tests (SST) - Part 1
18.12.2025PharmaLab 2025: Brief Summary of AQCG Track - Save the Date for 2026!
18.12.2025FDA Warning Letter: 1,500 OOS Results with Numerous Inadequate Investigations
17.12.2025FDA Warning Letter Criticises Handling of OOS Results at a Contract Laboratory
17.12.2025FDA Warning: No Recall Conducted Despite Confirmed Benzene Impurity